[1]罗佳文,张彩霞.肿瘤核素靶向治疗的研究进展[J].国际放射医学核医学杂志,2008,32(4):206-208,256.
 LUO Jia-wen,ZHANG Cai-xia.Research progess on treatment of cancer with targeted radionuclide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):206-208,256.
点击复制

肿瘤核素靶向治疗的研究进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第4期
页码:
206-208,256
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Research progess on treatment of cancer with targeted radionuclide therapy
作者:
罗佳文 张彩霞
110004 沈阳, 中国医科大学附属盛京医院核医学科
Author(s):
LUO Jia-wen ZHANG Cai-xia
Department of Nuclear Medicine, Shenging Hosphd of China Medwd University, Shenyang 110004, China
关键词:
放射疗法综合疗法吲哚美辛
Keywords:
RadiotherapyCombined modality therapyhtomethacin
摘要:
对近年来肿瘤核素靶向治疗的现状及进展进行了论述,包括放射免疫治疗、受体介导的靶向治疗、基因靶向治疗及化疗药物联合核素治疗四个大类,侧重介绍了这些治疗方法的常用标记载体的应用研究。同时,突出介绍了吲哚美辛的最新研究进展,并展望该药与核素靶向治疗联合应用的潜在研究价值。
Abstract:
The new development and situation of targeted radionuclide therapy in oncology is described,which include radioimmunotherapy,peptide receptor radionuclide therapy,gene therapy and radionuclide labled chemotherapeuties therapy.The application research on labled carrier of those therapy is emphasized.Meanwhile,the research pmgess of indomethacin and its combined with targeted radionuclide therapy is also described.

参考文献/References:

[1] 王荣福.肿瘤核素诊治现状与进展[J].同位素,2006,19(2): 112-118.
[2] Tumor JH,Martindale AA,Boucek J,et al.131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma:a phase Ⅱ clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital[J]. Cancer Biother Radiopharm,2003,18(4):513-524.
[3] Scott AM,Lee FT,Jones R.et al.A phase Ⅰ trial of humanized monoclonal antibody A33 in patients with eolorectal carcinoma: biodistribution,pharmacokineties,and quantitative tumor uptake[J].ClinCancerRes,2005,ll (13):4810-817.
[4] 王荣福.肿瘤受体显像//蒋宁一.肿瘤核医学[M].北京:人民卫生出版社.2002:256-268.
[5] Sward C,Bernhardt P,Johanson V,et al.Comparison of[1771u-DOTAO,Tyr3]-oetrotate and[1771u-DOTAO,Thy3]-oetemtide for receptor-meditated raditation therapy of the xenografted human midgut carcnoid tumor GOTl[J].Cancer Biother Radiopharm, 2008,23(1):114-120.
[6] Waldherr C,Pless M,Maecke HR.et al.The clinical value of -[90Y-DOTA]-D-PheI-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neurcendocrine tumors:a clinical phase Ⅱ study[J].Ann Oneol,2001,12(7):941-945.
[7] Schumaeher T,Hofer S,Eiehhorn K,et al.Local injiection of the 90Y-labelled pcptidic vector DOTATOC to control gliomas of WHO grades Ⅱ and Ⅲ: an extended pilot study[J].Ear J Nucl Med Mol Imaging,2002,29(4):486-493.
[8] Boland A,Ricard M,Opolon P,et al.Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy[J].Cancer Res,2000,60(13):3484-3492.
[9] Germarm C,Shields AF.Griersion JR,et al.5-Fluoro-1-(2’-deoxy-2’-fluoro-beta-D-ribofuranoayl) uracil trapping in Morris hepatoma cells expressing the herpes simplex virus thymidine kinase gene[J].J Nucl Med,1998,39(8):1418-1423.
[10] Wagner HN Jr.2003 SNM Highlights Lecture:From proof of principle to proof of value[J].J Nuel Med,2003,44(8):11N-36N.
[11] xu MH,Zhang GY.Effect of indomethacin on cell cycle proteins in colon cancer celll lines[J].World J Gaatroenterol,2005,11(11):1693-1696.
[12] Mima S,Takehara M,Takada H,et al.NSAIDs suppress the expression of claudin-2 to promote invasion activity of cancer cells[J].Carcinogenesis,2008,29(10):1994-2000.
[13] Grégoire V,Hunter NR,Brock WA,et al.Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethaein plus fludarabine[J].Radiat Res,1996,146(5): 548-553.
[14] Kishi K,Petersen S,Petersen C,et al.Preferential enhancement of tumor radioresponse by a eyclooxygenase-2 inhibitor[J].Cancer Res,2000,60(5):1326-1331.
[15] 周丽坤,张彩霞.氚标记吲哚美辛的亲肿瘤实验研究[J].中华核医学杂志,2004,24(4):209-210.
[16] 陈春梅,张彩霞,刁尧,等.口引哚美辛对荷瘤小鼠抗肿瘤作用机制的实验研究[J].同位素,2006,19(1):22-27.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
 Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
 Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[3]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
 Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[4]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
 Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[5]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
 Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[6]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
 Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[7]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
 zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
 Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]段永璇,邹晓艳,段秀梅,等.数据解析在肿瘤放射治疗中的应用[J].国际放射医学核医学杂志,2015,39(6):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
 Duan Yongxuan,Zou Xiaoyan,Duan Xiumei,et al.Data analysis in the field of tumor radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
[10]贾立立,孟粹达,刘晓冬,等.头颈部肿瘤放疗中转化医学相关机制的研究进展[J].国际放射医学核医学杂志,2015,39(3):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
 Jia Lili,Meng Cuida,Liu Xiaodong,et al.Development in translational medicine-related mechanisms of radiotherapy for head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
[11]杨坤禹,胡豫.抗肿瘤血管新生联合放射治疗研究进展[J].国际放射医学核医学杂志,2006,30(2):122.
 YANG Kun-yu,HU Yu.The progress on anti-angiogenesis combined with radiotherapy in malignancies[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):122.

备注/Memo

备注/Memo:
收稿日期:2008-01-23。
基金项目:辽宁省教育厅重点课题项目(20060919)
通讯作者:张彩霞,E-mail:wclzex@163.com
更新日期/Last Update: 1900-01-01